reason report
eptinezumab pdufa date new trial surpris acut
result updat investor progress lead asset
eptinezumab track commerci launch
migrain prevent prescript drug user free act pdufa
date februari compani remain posit
potenti commerci opportun eptinezumab migrain
categori even three calcitonin gene-rel peptid cgrp
inhibitor alreadi market steep discount compani
believ eptinezumab well differenti quarterli infus
dose excel efficaci safeti profil alder manag
also announc intent start new phase trial eptinezumab
acut treatment migrain second half
like larg market opportun alder compar
prevent compani explain product stock
use er acut sever migrain treatment could enhanc
competit posit overal class alder report net loss
expect driven higher
spend relat secur manufactur capac initi build
commerci inventori prepar launch eptinezumab
significantli higher sg due one-tim loss conting
provis relat contract disput total expens
quarter total
compar expect consensu
respect sg alder
end first quarter higher share count prior quarter
due underwritten public offer concurr privat placement
net proce million despit higher burn rate
compani maintain exist full year expens guidanc
compani report cash balanc accord
manag current cash suffici meet project
oper requir anticip launch eptinezumab
latter part compani reiter full year
guidanc oper expens net cash use oper activ
purchas properti equip
net debt total capit
per share net cash per share end
share outstand mil
year price history/av daili volume mil aldr
compani inform svb leerink llc research
revenu mm ep present
pleas refer page import disclosur price chart analyst certif
rate aldr share outperform alder biopharmaceut late stage biotechnolog
compani guid develop lead product eptinezumab monoclon antibodi
seek prophylax migrain eptinezumab member larg emerg class
anti-cgrp anti-calcitonin gene relat peptid cgrp area heavi competit
partner nv teva aldr announc posit data two pivot
studi migrain prophylaxi recent file bla epti
us potenti approv launch earli across anti-cgrp group aldr
compani develop iv though expect patient prefer at-hom
administr believ defined/differenti market exist durabl in-offic infus
physician make money
fda accept eptinezumab migrain prevent bla prepar
launch call alder manag confirm pdufa date eptinezumab bla
februari explain manufactur partner sandoz whose parent
novarti face litig partner contract alreadi start
produc launch-readi eptinezumab continu remaind year
alder explain sandoz provid guarante suppli drug substanc least five-
year term ad start commerci prepar launch includ
educ program hire key commerci execut
phase trial acut migrain treatment plan provid futur growth
opportun part eptinezumab life cycl manag compani plan initi
phase studi treatment acut migrain push iv mg dose eptinezumab vs
placebo secur treatment prevent label compani expect enhanc
competit contract posit
pipelin advanc toward migrain target high specif high affin
neutral monoclon antibodi reactiv pituitari adenyl cyclase-
activ peptid pacap view anoth import signal pathway
pathophysiolog migrain could account signific portion patient fail
respond cgrp alder advanc program target continu
advanc develop despit disappoint result competit program
altern cgrp alder still believ repres attract target
treatment prevent migrain acut toxicolog studi reveal advers effect
pre-clin studi compani plan initi first human studi end
made small updat expens forecast price target remain nearli
unchang given chang cash estim made minor
chang non-oper expens price target share
maintain outperform rate
estim price target aldr month use dcf analysi dcf
valuat employ discount rate termin growth rate believ
discount rate reason consid clinic stage compani dcf valuat
includ net cash dilut secur addit forecast cash flow believ
eptinezumab grow time achiev global risk-adjust sale
includ royalti outsid us includ probability-of-success iv
peak market share anti-cgrp market
risk valuat includ fda/ema approv risk eptinezumab risk
clinic program delay competit risk given presenc multipl anti-cgrp
antibodi manufactur risk risk disappoint clinic data risk dilut
ip royalti teva
licens clazakizumab
net incom loss equiti
dividend pref convert
net incom loss common
sec file svb leerink
alder bs cf mm
chang
sec file svb leerink
termin valu discount
brand
type event
event trial detail
date known
expect
accept bla file
svb leerink llc research compani file
